Objective: To evaluate the clinical safety of Fufang Ejiao Jiang in treatment of anemia. Method: In 2010 January-2011 December

1 200 cases of anemia were treated with Fufang Ejiao Jiang. After 1 months of treatment

evaluate the adverse drug reaction and the changes of classification of blood white blood cells

and the function of liver and kidney

and monitor the incidence of adverse reactions. Result: The incidence of adverse reaction rate was 0.83% on the 1 200 cases of anemia

the highest incidence was digestive system reaction

other adverse reactions rate was lower

such as Dizziness

nausea

vomiting

allergic reaction. and lasted for a short duration

all disappeared or improved. The changes of classification of leukocytes

transaminase

blood urea nitrogen

was little and no significant difference. Conclution: Fufang Ejiao Jiang is safe for treating anemia in clinical use.